Factors related to haloperidol response and dyskinesias in autistic children

J. J. Locascio, R. P. Malone, A. M. Small, V. Kafantaris, M. Ernst, N. S. Lynch, J. E. Overall, M. Campbell

Research output: Contribution to journalArticle

Abstract

A secondary analysis of data pooled from three studies (Anderson et al. 1984, 1989; Campbell et al. 1978) was performed to identify variables predictive of haloperidol response in 125 autistic children, with ages ranging from 2.3 to 8.2 years. Mean behavioral improvement was greater under haloperidol treatment conditions than under placebo. Higher intelligence quotient (IQ) was predictive of reduction in behavioral symptoms under general conditions of haloperidol or placebo treatment, while older children were found to respond favorably to haloperidol itself. Under both haloperidol and placebo conditions, there was also a tendency for greater reduction in symptoms, in terms of raw score and percent change, for those with greater initial severity of illness. Results for initial severity of illness as a predictor of improvement generalized across a wide variety of behavior not specific to autism (e.g., hyperactivity and temper outbursts). However, mean behavioral improvement and its prediction with demographics for individuals tended to be more specific to symptoms related to autism per se. Reduction in symptoms during short-term haloperidol treatment was not found to be related to whether or not children developed dyskinesias in subsequent long-term haloperidol administration.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalPsychopharmacology Bulletin
Volume27
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Dyskinesias
Haloperidol
Placebos
Autistic Disorder
Behavioral Symptoms
Intelligence
Therapeutics
Demography

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Locascio, J. J., Malone, R. P., Small, A. M., Kafantaris, V., Ernst, M., Lynch, N. S., ... Campbell, M. (1991). Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacology Bulletin, 27(2), 119-126.

Factors related to haloperidol response and dyskinesias in autistic children. / Locascio, J. J.; Malone, R. P.; Small, A. M.; Kafantaris, V.; Ernst, M.; Lynch, N. S.; Overall, J. E.; Campbell, M.

In: Psychopharmacology Bulletin, Vol. 27, No. 2, 1991, p. 119-126.

Research output: Contribution to journalArticle

Locascio, JJ, Malone, RP, Small, AM, Kafantaris, V, Ernst, M, Lynch, NS, Overall, JE & Campbell, M 1991, 'Factors related to haloperidol response and dyskinesias in autistic children', Psychopharmacology Bulletin, vol. 27, no. 2, pp. 119-126.
Locascio JJ, Malone RP, Small AM, Kafantaris V, Ernst M, Lynch NS et al. Factors related to haloperidol response and dyskinesias in autistic children. Psychopharmacology Bulletin. 1991;27(2):119-126.
Locascio, J. J. ; Malone, R. P. ; Small, A. M. ; Kafantaris, V. ; Ernst, M. ; Lynch, N. S. ; Overall, J. E. ; Campbell, M. / Factors related to haloperidol response and dyskinesias in autistic children. In: Psychopharmacology Bulletin. 1991 ; Vol. 27, No. 2. pp. 119-126.
@article{ddc97cfdb95744e3bd0f3557b0381a95,
title = "Factors related to haloperidol response and dyskinesias in autistic children",
abstract = "A secondary analysis of data pooled from three studies (Anderson et al. 1984, 1989; Campbell et al. 1978) was performed to identify variables predictive of haloperidol response in 125 autistic children, with ages ranging from 2.3 to 8.2 years. Mean behavioral improvement was greater under haloperidol treatment conditions than under placebo. Higher intelligence quotient (IQ) was predictive of reduction in behavioral symptoms under general conditions of haloperidol or placebo treatment, while older children were found to respond favorably to haloperidol itself. Under both haloperidol and placebo conditions, there was also a tendency for greater reduction in symptoms, in terms of raw score and percent change, for those with greater initial severity of illness. Results for initial severity of illness as a predictor of improvement generalized across a wide variety of behavior not specific to autism (e.g., hyperactivity and temper outbursts). However, mean behavioral improvement and its prediction with demographics for individuals tended to be more specific to symptoms related to autism per se. Reduction in symptoms during short-term haloperidol treatment was not found to be related to whether or not children developed dyskinesias in subsequent long-term haloperidol administration.",
author = "Locascio, {J. J.} and Malone, {R. P.} and Small, {A. M.} and V. Kafantaris and M. Ernst and Lynch, {N. S.} and Overall, {J. E.} and M. Campbell",
year = "1991",
language = "English (US)",
volume = "27",
pages = "119--126",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Factors related to haloperidol response and dyskinesias in autistic children

AU - Locascio, J. J.

AU - Malone, R. P.

AU - Small, A. M.

AU - Kafantaris, V.

AU - Ernst, M.

AU - Lynch, N. S.

AU - Overall, J. E.

AU - Campbell, M.

PY - 1991

Y1 - 1991

N2 - A secondary analysis of data pooled from three studies (Anderson et al. 1984, 1989; Campbell et al. 1978) was performed to identify variables predictive of haloperidol response in 125 autistic children, with ages ranging from 2.3 to 8.2 years. Mean behavioral improvement was greater under haloperidol treatment conditions than under placebo. Higher intelligence quotient (IQ) was predictive of reduction in behavioral symptoms under general conditions of haloperidol or placebo treatment, while older children were found to respond favorably to haloperidol itself. Under both haloperidol and placebo conditions, there was also a tendency for greater reduction in symptoms, in terms of raw score and percent change, for those with greater initial severity of illness. Results for initial severity of illness as a predictor of improvement generalized across a wide variety of behavior not specific to autism (e.g., hyperactivity and temper outbursts). However, mean behavioral improvement and its prediction with demographics for individuals tended to be more specific to symptoms related to autism per se. Reduction in symptoms during short-term haloperidol treatment was not found to be related to whether or not children developed dyskinesias in subsequent long-term haloperidol administration.

AB - A secondary analysis of data pooled from three studies (Anderson et al. 1984, 1989; Campbell et al. 1978) was performed to identify variables predictive of haloperidol response in 125 autistic children, with ages ranging from 2.3 to 8.2 years. Mean behavioral improvement was greater under haloperidol treatment conditions than under placebo. Higher intelligence quotient (IQ) was predictive of reduction in behavioral symptoms under general conditions of haloperidol or placebo treatment, while older children were found to respond favorably to haloperidol itself. Under both haloperidol and placebo conditions, there was also a tendency for greater reduction in symptoms, in terms of raw score and percent change, for those with greater initial severity of illness. Results for initial severity of illness as a predictor of improvement generalized across a wide variety of behavior not specific to autism (e.g., hyperactivity and temper outbursts). However, mean behavioral improvement and its prediction with demographics for individuals tended to be more specific to symptoms related to autism per se. Reduction in symptoms during short-term haloperidol treatment was not found to be related to whether or not children developed dyskinesias in subsequent long-term haloperidol administration.

UR - http://www.scopus.com/inward/record.url?scp=0025833468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025833468&partnerID=8YFLogxK

M3 - Article

C2 - 1924657

AN - SCOPUS:0025833468

VL - 27

SP - 119

EP - 126

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -